Clinical Trial

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

Completed
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to better understand factors contributing to variations in hydroxyurea (HU) adherence behavior in adolescents and young adults (AYA) with sickle cell disease (SCD). To meet this objective, the researchers will conduct a prospective cohort study to determine the longitudinal relationship between HU adherence and health-related quality of life (HRQOL) overtime among AYA with SCD. The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-01
notable Primary completion moved earlier: 2025-06-01 -> 2024-06-18 2026-08-01
minor Completion moved earlier: 2025-12-01 -> 2025-05-29 2026-08-01
Trial Details
NCT Number NCT04691323
Lead Sponsor Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Enrollment 68 participants
Start Date 2021-03-02
Primary Completion 2024-06-18 (estimated)
Study Completion 2025-05-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-31